Research programme: skin disorders RNAi therapies - SomaGenicsAlternative Names: Skin disorders siRNA therpeutics
Latest Information Update: 26 Dec 2014
At a glance
- Originator SomaGenics
- Mechanism of Action Genetic transcription inhibitors; RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 16 Aug 2005 Preclinical trials in Skin disorders in USA (Injection)